While Herceptin is being used as a first-line drug treatment for HER2-positive breast cancer, about 52% of breast cancer patients fail to respond to the initial Herceptin treatment or develop resistance to the antibody therapy within one year (9–11). This evidence concerns the gene ERBB2 and breast cancer.